Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Vet Emerg Crit Care (San Antonio) ; 22(3): 332-40, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22612729

RESUMO

OBJECTIVES: To determine the frequency of delayed postoperative bleeding in retired racing Greyhounds with appendicular bone tumors undergoing limb amputations. To identify if administration of epsilon-aminocaproic acid (EACA) was effective on the prevention of postoperative bleeding. DESIGN: Retrospective study from December 2003 to December 2008. SETTING: Veterinary university teaching hospital. ANIMALS: Forty-six retired racing Greyhounds (RRGs) diagnosed with primary appendicular bone tumors that underwent limb amputation were included in the study. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thirteen of 46 RRGs (28%) included in the study had delayed postoperative bleeding starting 48-72 h after surgery. Bleeding episodes included cutaneous, subcutaneous, and external bleeding that extended from the area of the surgical site that became widespread within hours, and that required administration of blood components. A paired t-test suggests that there was a significant decrease in PCV postoperatively for both dogs that bled and dogs that did not bleed (P < 0.0001). Forty of 46 RRGs (86%) received either fresh frozen plasma (FFP) or EACA or both, for the prevention of postoperative bleeding. A logistic regression model determined that dogs that did not receive EACA were 5.7 times more likely to bleed than dogs that did receive EACA, when controlling for whether or not they received FFP (95% CI: 1.02-32.15, P = 0.047). CONCLUSION: This retrospective study suggests that preemptive postoperative administration of EACA appears to be efficacious in decreasing the frequency of bleeding in RRGs undergoing limb amputation; however, a prospective study is warranted to corroborate its effectiveness.


Assuntos
Ácido Aminocaproico/uso terapêutico , Amputação Cirúrgica/veterinária , Antifibrinolíticos/uso terapêutico , Neoplasias Ósseas/veterinária , Doenças do Cão/prevenção & controle , Hemorragia/veterinária , Amputação Cirúrgica/efeitos adversos , Animais , Neoplasias Ósseas/cirurgia , Doenças do Cão/genética , Doenças do Cão/cirurgia , Cães , Predisposição Genética para Doença , Hemorragia/genética , Hemorragia/prevenção & controle , Osteossarcoma/cirurgia , Osteossarcoma/veterinária , Complicações Pós-Operatórias/prevenção & controle , Complicações Pós-Operatórias/veterinária , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...